A5077285985- Treatment of Major Depression
- Mental Health Research Topics
- Schizophrenia research and treatment
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Bipolar Disorder and Treatment
- Digital Mental Health Interventions
- Mental Health Treatment and Access
- Electroconvulsive Therapy Studies
- Neurotransmitter Receptor Influence on Behavior
- Mental Health and Psychiatry
- Health Systems, Economic Evaluations, Quality of Life
- Substance Abuse Treatment and Outcomes
- Health Policy Implementation Science
- Suicide and Self-Harm Studies
- Opioid Use Disorder Treatment
- Child and Adolescent Psychosocial and Emotional Development
- Diet and metabolism studies
- Cardiac Health and Mental Health
- Mental Health and Patient Involvement
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Coordination Chemistry and Organometallics
- Biomedical Ethics and Regulation
- Behavioral Health and Interventions
- Functional Brain Connectivity Studies
- Cannabis and Cannabinoid Research
The University of Texas Southwestern Medical Center
2006-2022
Texas Tech University
2021
University of California, San Francisco
2021
National Institute on Drug Abuse
2021
University of California, San Diego
2004
University of Kansas
2004
University of Pittsburgh
2004
University of Illinois Chicago
2004
Massachusetts General Hospital
2004
Austin College
1998
Selective serotonin reuptake inhibitors (SSRIs) are widely used to treat depression, but the rates, timing, and baseline predictors of remission in "real world" patients not established. The authors' primary objectives this study were evaluate effectiveness citalopram, an SSRI, using measurement-based care actual practice, identify symptom outpatients with major depressive disorder.This clinical included disorder who treated 23 psychiatric 18 settings. received flexible doses citalopram...
After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant more effective than another.We randomly assigned 727 adult outpatients nonpsychotic major depressive disorder who had no remission of symptoms or could tolerate the SSRI citalopram receive following drugs up 14 weeks: sustained-release bupropion (239 patients) at maximal daily dose 400 mg, sertraline (238 200 extended-release venlafaxine...
Although clinicians frequently add a second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has compared the efficacy of this approach.
Background. The present study provides additional data on the psychometric properties of 30-item Inventory Depressive Symptomatology (IDS) and recently developed Quick (QIDS), a brief 16-item symptom severity rating scale that was derived from longer form. Both IDS QIDS are available in matched clinician-rated (IDS-C 30 ; QIDS-C 16 ) self-report (IDS-SR QIDS-SR formats. Method. patient samples included 544 out-patients with major depressive disorder (MDD) 402 bipolar (BD) drawn 19 regionally...
Objective: More than 40% of patients with major depressive disorder do not achieve remission even after two optimally delivered trials antidepressant medications. This study compared the effectiveness lithium versus triiodothyronine (T 3 ) augmentation as a third-step treatment for disorder. Method: A total 142 adult outpatients nonpsychotic who had achieved or were intolerant to an initial prospective citalopram and second switch trial randomly assigned (up 900 mg/day; N=69) T 50 μg/day;...
Background. Anxious depression, defined as Major Depressive Disorder (MDD) with high levels of anxiety symptoms, may represent a relatively common depressive subtype, distinctive features. Objective. The objective this study was to determine the prevalence anxious depression and define its clinical correlates symptom patterns. Method. Baseline sociodemographic data were collected on 1450 subjects participating in STAR*D study. A baseline Hamilton Rating Scale for Depression (HAM-D)...
Objective: The purpose of this study was to compare the effectiveness and tolerability tranylcypromine combination treatment with extended-release venlafaxine mirtazapine in patients treatment-resistant major depression whose current depressive episode had not responded adequately three prior prospective medication trials. Method: Adult outpatients nonpsychotic disorder who achieved remission or withdrawn from because intolerance previous trials were randomly assigned receive open-label...
The use of naltrexone plus bupropion to treat methamphetamine disorder has not been well studied. We conducted this multisite, double-blind, two-stage, placebo-controlled trial with the a sequential parallel comparison design evaluate efficacy and safety extended-release injectable (380 mg every 3 weeks) oral (450 per day) in adults moderate or severe disorder. In first stage trial, participants were randomly assigned 0.26:0.74 ratio receive naltrexone-bupropion matching placebo for 6 weeks....
<h3>Context</h3> The Texas Medication Algorithm Project is an evaluation of algorithm-based disease management program for the treatment self-declared persistently and seriously mentally ill in public mental health sector. <h3>Objective</h3> To present clinical outcomes patients with major depressive disorder (MDD) during 12-month algorithm-guided (ALGO) compared as usual (TAU). <h3>Design</h3> Effectiveness, intent-to-treat, prospective trial comparing patient clinics offering ALGO matched...
Article Abstract Objective: To determine the frequency and demographic clinical characteristics of depression with atypical features in a broadly representative sample outpatients. Method: Data derived from first 1500 patients DSM-IV major depressive disorder enrolled Sequenced Treatment Alternatives to Relieve Depression trial at 41 primary care nonresearch psychiatric outpatient clinics. An algorithm based on 30-item Inventory Depressive Symptomatology-Clinician Rating (IDS-C30) determined...
Objective: We previously found that 46% of the first 1450 outpatients with depression participating in multicentre Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project qualified for designation anxious depression. This study was designed replicate and extend our initial findings a subsequent, larger cohort outpatient STAR*D participants nonpsychotic major depressive disorder (MDD). Methods: Baseline clinical sociodemographic data were collected on 2337 consecutive...
Background Depression is characterized by poor executive function, but – counterintuitively in some studies, it has been associated with highly accurate performance on certain cognitively demanding tasks. The psychological mechanisms responsible for this paradoxical finding are unclear. To address issue, we applied a drift diffusion model (DDM) to flanker task data from depressed and healthy adults participating the multi-site Establishing Moderators Biosignatures of Antidepressant Response...
Article AbstractThis article provides an overview of the issues involved in developing, using, and evaluating specific medication guidelines for patients with psychiatric disorders. The potential advantages disadvantages, as well essential elements structure algorithms, are illustrated by experience to date Texas Medication Algorithm Project, a public-academic collaboration. Phase 1 entailed assembling research findings on efficacy medications schizophrenic, bipolar, major depressive This...
Article Abstract Background: Medication treatment algorithms may improve clinical outcomes, uniformity of treatment, quality care, and efficiency. However, such benefits have never been evaluated for patients with severe, persistent mental illnesses. This study compared economic outcomes an algorithm-driven disease management program (ALGO) treatment-as-usual (TAU) adults DSM-IV schizophrenia (SCZ), bipolar disorder (BD), major depressive (MDD) treated in public health outpatient clinics...
This study evaluated the concordance between self-report and clinician-rated versions of Inventory Depressive Symptomatology (IDS-30) two briefer 16-item Quick (QIDS-16).Data were gathered for 544 adult outpatients with psychotic (N = 106) or nonpsychotic 438) major depressive disorder at 14 public sector mental health clinics in Texas Medication Algorithm Project. Data QIDS-16 extracted from IDS-30. Baseline scores final visit before month 12 analyzed. The each scale compared their...
Article Abstract Background: The Texas Medication Algorithm Project (TMAP) assessed the clinical and economic impact of algorithm-driven treatment (ALGO) as compared with treatment-as-usual (TAU) in patients served public mental health centers. This report presents outcomes a history mania (BD), including bipolar I schizoaffective disorder, type, during 12 months beginning March 1998 ending final active patient visit April 2000. Method: Patients were diagnosed disorder or according to DSM-IV...
Attrition rates are high during treatment for major depressive disorder (MDD), and patients who drop out less likely to reach remission. This report evaluates the incidence, timing, predictors of attrition second-step medication treatment. Outpatients in multisite Sequenced Treatment Alternatives Relieve Depression (STAR*D) study receiving a augmentation (n=563) or switch (n=723) non-psychotic MDD after an unsatisfactory outcome with citalopram were evaluated determine pretreatment...
To evaluate exercise as a treatment for stimulant use disorders.The STimulant Reduction Intervention using Dosed Exercise (STRIDE) study was randomized clinical trial conducted in 9 residential addiction programs across the United States from July 2010 to February 2013. Of 497 adults referred study, 302 met all eligibility criteria, including DSM-IV criteria abuse and/or dependence, and were either dosed intervention (Exercise) or health education (Health Education) control, both augmenting...